Details
Flutafarm Indications
Treatment of locally advanced or metastatic prostate cancer as monotherapy (with or without orchiectomy) or in combination with luteinizing hormone-releasing hormone (LHRH) agonists in patients who have not previously received any treatment or in patients who have not responded or developed to hormone therapy or its intolerance in order to achieve maximum androgen blockade.
In combination therapy, it is used to treat locally limited prostate cancer B2-C2 (T2b-T4), to reduce tumor volume, to strengthen tumor control, and to increase the period between exacerbations.
Treatment of women with functional hyperandrogenism, which is accompanied by ovarian-menstrual disorders, hirsutism, scleropolycystic ovary syndrome and infertility.
Contradictions
Hypersensitivity to flutamide or to other components of the drug. For women, additional contraindications to taking Flutafarm® are hyperandrogenism of organic origin (ovarian and adrenal cortex tumors). Severe hepatic impairment (baseline liver enzymes should be assessed prior to treatment).
Children's age.
Dosage & Administration
The drug is taken orally.
Flutapharm® should be prescribed to patients with prostate cancer as monotherapy (after or without orchiectomy) or in combination with LHRH agonists 1 tablet (250 mg) 3 times a day every 8 hours. The daily dose is 750 mg.
In the case of combination therapy with LHRH agonists, both drugs can be prescribed simultaneously or Flutafarm® should be started 3 days before the start of LHRH agonist therapy.
In case of radiation therapy, Flutapharm® should be prescribed 8 weeks before its start and continue taking the drug throughout the course of radiation therapy.
Women with hyperandrogenic conditions should be given Flutapharm® orally 1/2 tablet (125 mg) 3 times a day for 3 to 6 months. Take during or after meals. The use of non-hormonal contraceptives, including barrier contraceptives, is mandatory.
